Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 421-090-1 | CAS number: 131298-44-7 Isodecyl benzoate
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
Reverse Mutation assay (1996). Acceptable, well-documented study report equivalent or similar to OECD 471. Isodecyl Benzoate was tested at 312.5, 625, 1250, 2500, and 5000 ug/plate levels with and without S-9 metabolic activation. Isodecyl Benzoate did not produce evidence of mutagenic activity in the bacterial systems tested, either in the presence or absence of metabolic activator.
In vitro mammalian chromosome aberration test (1995). Acceptable, well-documented study report equivalent or similar to OECD 473 and EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test) Human lymphocytes.
First test: 9.8, 19.5, 39.1, 78.1, 156.3, 312.5, 625, 1250, 2500, and 5000 ug/mL levels (w/ and w/out S-9)
Second test:Harvested after 18 hours (w/ S-9) 625, 1250, 2500, and 5000 ug/mL
Second test:Harvested after 18 hours (w/out S-9) 9.8, 19.5, 39.1, 78.1, 156.3, 312.5, 625, 1250, 2500, and 5000 ug/mL
Second test:Harvested after 32 hours (w/ S-9) 625, 1250, 2500, and 5000 ug/mL
Second test:Harvested after 32 hours (w/out S-9) 9.8, 19.5, 39.1, 78.1, 156.3, 312.5, 625, 1250, 2500, and 5000 ug/mL
Third test: Harvested after 18 hours (w/ S-9) 100, 156.3, 225, 312.5 ug/mL
First Test
Toxicity Data:
In the absence of S-9 mix Isodecyl benzoate was toxic, with the relative mitotic index being reduced to 19% of the solvent control value at 156.3 ug/mL. The dose levels selected for metaphase analysis were 19.5, 39.1, and 78.1 ug/mL. The mitotic index was reduced to 53% at 78.1 ug/mL.
In the presence of S-9 mix Isodecyl benzoate was non-toxic in terms of depression of mitotic index. The dose levels selected for analyses were 625, 2500 and 5000 ug/mL.
Metaphase analysis:
In the absence of S-9 mixthere were no statistically significant increases in the proportion of aberrant cells when compared to the solvent control.
In the presence of S-9 mixa statistically significant increase in the proportion of aberrant cells was seen at the highest dose level analysed (5000 ug/mL). The levels of 6.5% and 7.0% excluding and including gap damage, respectively, lay just outside the historical control range (0 0 5.25% excluding gap damage and 0 - 6.25% including gap damage).
Bothpositive control compounds, ethyl methanesulphonate and cyclophosphamide, caused large, statistically significant increases (P<0.001) in the proportion of aberrant cells. This demonstrated the efficacy of the S-9 mix and the sensitivity of the test systems.
Second Test
Toxicity Data:
In the absence of S-9 mixIsodecyl benzoate was toxic with a reduction of the mitotic index to 16% or less when compared to the control at concentrations of 156.3 ug/mL and above. The three dose levels chosen for analysis were 19.5, 39.1, and 78.1 ug/mL.
In the presence of S-9 mixIsodecyl benzoate was non-toxic in terms of depression of mitotic index. The dose levels selected for analysis were the same as for the first test, i.e. 625, 2500 and 5000 ug/mL.
The concentrations of the positive control compounds selected for analysis were ethyl methanesulphonate at 500 ug/mL and cyclophosphamide at 15 ug/mL.
Metaphase analysis:
No statistically significant increases in the proportion of aberrant cells when compared to the solvent control were seen in either the presence or absence of S-9 mix.
Bothpositive control compounds, ethyl methanesulphonate and cyclophosphamide, caused large, statistically significant increases (P < 0.001) in the proportion of aberrant cells.
Second test - 32 hour harvest:
Toxicity data
In the absence of S-9 mixIsodecyl benzoate was toxic at concentrations of 156.3 ug/mL and above, with the relative mitotic index being reduced to 9% or less. The dose level selected for analysis was 78.1 ug/mL
In the presence of S-9 mixIsodecyl benzoate was non-toxic and the highest dose level, 5000 ug/mL, was selected for analysis.
The concentrations of the positive control compounds selected for analysis were ethyl methanesulphonate and 500 ug/mL and cyclophosphamide at 5 ug/mL.
Metaphase analysis:
No statistically significant increases in the proportion of aberrant cells when compared to the solvent control were seen in either the presence or absence of S-9 mix.
Both positive control compounds, ethyl methanesulphonate and cyclophosphamide, caused large, statistically significant increases (P < 0.001) in the proportion of aberrant cells.
The increase in aberrant cells seen in the first test in the presence of S-9 mix was not considered to be indicative of clastogenic activity for the following reasons:
1 The response did not greatly exceed the upper limit of the historical control range.
2 The response was not reproduced in the second test.
3 The response was not seen at the later harvest time.
Third test - 18 hour harvest
Toxicity data:
In the presence of S-9 mixIsodecyl benzoate was non-toxic in terms of depression of mitotic index, at all dose levels. The reduction seen at the middle range of dose levels in the first test was, therefore, considered to be anomalous. The dose levels selected for analysis were 100, 156.3, 225, and 312.5 ug/mL. The highest dose level, 312.5 ug/mL, was selected as it was the lowest insoluble concentration. The lower three dose levels were all soluble. The consentration of cyclophosphamide selected for was 25 ug/mL.
Metaphase analysis:
No statistically significant increases in the proportion of the aberrant cells when compared to the solvent controlwere seen.
The positive control, cyclophosphamide, caused a large, statistically significant increase (P < 0.001) in the proportion of aberrant cells. This demonstrated the efficacy of the S-9 mix and the sensitivity of the test system.
Isodecyl Benzoate did not produce evidence of clastogenic activity in the in vitro cytogenetic test system, either in the presence or absence of metabolic activator. It was concluded that Isodecyl Benzoate showed not evidence of clastogenic activity in the in vitro cytogenetic test system.
Chromosome aberration, micronucleus assay. Acceptable, well-documented study report equivalent or similar to OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test). (1995).
All animals in all groups were dosed with the standard volume of 20 mL/kg bodyweight or 1280 mg/kg bodyweight. Test substance and negative control were dosed by intraperitoneal injection. Mitomycin C, the positive control, was dosed orally by intragastric gavage at 12 mg/kg bodyweight. The animals in the the postive control group were deprived of diet overnight prior to and two hours after dosing. 15 animals per sex (male/female) 30 animals total per dose (Vehicle/Isodecyl Benzoate; 1280 mg/kg B-wt ), 5 animals per sex (male/female) and 10 animals total per dose (Mitomycin C). Bone marrow smears were obtained from test substance and negative control groups at 24, 48 and 72 hours after dosing. Bone marrow smears were obtained form the positive control group at 24 hours after dosing.
Isodecyl benzoate, when adminsitered by intraperitoneal injection at 1280 mg/kg bodyweight, did not cause a substantial increase in the incidence of micronucleated polychromatic erythroytes. Isodecyl benzoate did not show evidence of causing chromosome damage in this in vivo test. Isodecyl benzoate produced bone marrow cell toxicity/depression as indicated by a statistically significant decrease in the ratio of polychromatic to normochromatic erythrocytes obtained for treated animals.
Short description of key information:
CAS RN 131298-44-7 was negative when tested in: the Reverse mutation assay (Ames Test) with S. typhimurium TA 1535, TA 1537, TA 98 and TA 100, with and without S-9 metabolic activation; the In vitro mammalian chromosome aberration test (human lymphocytes, with and witout S-p metabolic activation; and, the Chromosome aberration, mouse micronucleus assay. It did not cause a substantial increase in the incidence of micronucleated polychromatic erythroytes and did not show evidence of causing chromosome damage in this in vivo test. It produced bone marrow cell toxicity/depression as indicated by a statistically significant decrease in the ratio of polychromatic to normochromatic erythrocytes obtained for treated animals.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
CAS RN 131298-44-7 was negative when tested in: the Reverse mutation assay (Ames Test) with S. typhimurium TA 1535, TA 1537, TA 98 and TA 100, with and without S-9 metabolic activation; the In vitro mammalian chromosome aberration test (human lymphocytes, with and witout S-p metabolic activation; and, the Chromosome aberration, mouse micronucleus assay. It did not cause a substantial increase in the incidence of micronucleated polychromatic erythroytes and did not show evidence of causing chromosome damage in this in vivo test. It produced bone marrow cell toxicity/depression as indicated by a statistically significant decrease in the ratio of polychromatic to normochromatic erythrocytes obtained for treated animals.
No classification for genetic toxicity is indicated according to the general classification and labeling requirements for dangerous substances and preparations (Directive 67-548-EEC) or the classification, labeling and packaging (CLP) regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.